Related Experiment Video

Updated: Apr 5, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Fyn is an important molecule in cancer pathogenesis and drug resistance

Daniel Elias1, Henrik J Ditzel2

  • 1Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Pharmacological Research
|August 26, 2015
PubMed

Insights

Fyn tyrosine kinase is upregulated in tamoxifen-resistant breast cancer, driving resistance. Its cellular localization may predict prognosis, suggesting Fyn as a therapeutic target for improved cancer management.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Fyn is a non-receptor tyrosine kinase in the Src family kinases (SFKs).
  • Fyn regulates crucial cellular processes including signal transduction, T-lymphocyte activation, cell growth, and motility.
  • Aberrant Fyn expression is implicated in various cancers, including melanoma, glioblastoma, and breast cancer.

Purpose of the Study:

  • To investigate the role of Fyn in tamoxifen resistance in breast cancer.
  • To explore Fyn's potential as a prognostic marker in estrogen receptor-positive (ER+) breast tumors.
  • To understand Fyn's contribution to cancer progression and therapeutic resistance.

Main Methods:

  • Analysis of Fyn expression in tamoxifen-resistant breast cancer cell lines.
  • Investigation of Fyn's role in the resistance mechanism.
  • Evaluation of Fyn cellular localization in primary ER+ breast tumor tissues.

Main Results:

  • Fyn is upregulated in tamoxifen-resistant breast cancer cell lines.
  • Fyn plays a significant role in mediating tamoxifen resistance.
  • Cellular localization of Fyn in primary ER+ breast tumors correlates with prognostic outcomes.

Conclusions:

  • Fyn upregulation is a key mechanism of tamoxifen resistance in breast cancer.
  • Fyn cellular localization can serve as a prognostic biomarker for ER+ breast cancer.
  • Targeting Fyn may offer a novel therapeutic strategy for managing breast cancer and other malignancies.
Keywords:
CancerDrug resistanceFynSrc family kinase

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.8K
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K